Figure S2

MSC
MSC + TNFa
MSC + TNFa +0.1ug/ml LPS
MSC + TNFa + 1ug/ml LPS
MSC + TNFa + 5ug/ml LPS
MSC + TNFa + 10ug/ml LPS
MSC + TNFa + 20ug/ml LPS

Arg1

MSC
MSC + TNFa
MSC + TNFa +0.1ug/ml LPS
MSC + TNFa + 1ug/ml LPS
MSC + TNFa + 5ug/ml LPS
MSC + TNFa + 10ug/ml LPS
MSC + TNFa + 20ug/ml LPS

CD206

MSC
MSC + TNFa
MSC + TNFa +0.1ug/ml LPS
MSC + TNFa + 1ug/ml LPS
MSC + TNFa + 5ug/ml LPS
MSC + TNFa + 10ug/ml LPS
MSC + TNFa + 20ug/ml LPS

TNFa/IL1Ra

MSC
MSC + TNFa
MSC + TNFa +0.1ug/ml LPS
MSC + TNFa + 1ug/ml LPS
MSC + TNFa + 5ug/ml LPS
MSC + TNFa + 10ug/ml LPS
MSC + TNFa + 20ug/ml LPS
Figure S3

Alizarin Red S

OD 562

Untreated Celecoxib Week 1-3 Celecoxib Week 1 Celecoxib Week 2 Celecoxib Week 3

***

*
Figure S4

![Graph showing iNOS expression levels for different treatments.](image)

- **MO Untreated**
- **MO LPS+TNFα**
- **MO TNFα**
- **MO LPS**

The graph demonstrates a significant increase in iNOS expression for MO LPS+TNFα compared to other treatments. The y-axis represents the fold of unstimulated MSC. The bars are labeled with *** to indicate statistical significance.